Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)
October 10, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies
September 16, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Reports Results for the Second Quarter Ended June 30, 2019
August 06, 2019 16:00 ET
|
Aptose Biosciences, Inc.
─ APTO-253 Inhibits MYC in AML and MDS Patients in Phase 1 Clinical Trial ─ ─ First CLL Patient Dosed with CG-806 in Phase 1 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today ...
Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference
July 30, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019
July 23, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
July 16, 2019 07:05 ET
|
Aptose Biosciences, Inc.
– CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – APTO-253 MYC inhibitor being developed for the...
Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
June 14, 2019 07:00 ET
|
Aptose Biosciences, Inc.
– CG-806 safely and durably suppressed tumor growth in preclinical models – SAN DIEGO and TORONTO, June 14, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:...
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
June 04, 2019 16:02 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer
June 03, 2019 09:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose to Present at the Jefferies 2019 Healthcare Conference
May 31, 2019 08:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 31, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...